With $1.8 billion in revenue for 2020, PerkinElmer Diagnostics is a major player in the in vitro diagnostics market. Operating on a global scale, PerkinElmer’s large product portfolio serves multiple end users and needs. We offer innovative and complete solutions, including instruments, reagents, automation, services and software, designed to improve the efficiency of reproductive health, immunodiagnostics, molecular diagnostics, and clinical chemistry workflows.
PerkinElmer has recently launched the Vanadis® cfDNA platform*, which is a fully-automated non-sequencing, non-PCR based solution for cell-free DNA analysis. Designed as an easy-to-use, cost-effective and scalable assay, Vanadis® cfDNA aims to increase access to cell-free DNA analysis to more laboratories. Requiring no genetic expertise to operate, Vanadis® cfDNA is built for all.
*For Research Use Only. Not for use in diagnostic procedures.
Vanadis cfDNA Platform
940 Winter St, Waltham, MA 02451